Evotec Se · XETR:EVT
Evotec — Bank of America Merrill Lynch Global Healthcare Conference 2018
25 slides from Evotec's conference presentation, Sep 13, 2018
Slide 1: Evotec – Leading external innovation
Evotec – Leading external innovation Evotec AG, Company Presentation, Bank of America Merrill Lynch Global Healthcare Conference 2018, London, 13 September 2018
Slide 2: Forward-looking statement
Forward-looking statement Information set forth in this presentation contains forward-looking statements, which involve a number of risks and uncertainties. The forward-looking statements contained herein represent the judgement of Evotec as of the date of this presentation. Such forward-looking sta
Slide 3: Agenda
Agenda Overview EVT Execute EVT Innovate Financials & Outlook PAGE 2
Slide 4: Leading external innovation to accelerate new drugs
Leading external innovation to accelerate new drugs Evotec at a glance Evotec delivers a fast growing and profitable drug discovery and development business to Pharma, biotech and foundations Evotec and its partners are progressing a pipeline of approx. 100 co-owned first-in-class projects in ma
Slide 5: Consequent and fast forward – AP 2022
Consequent and fast forward – AP 2022 “Action Plan 2022 – Leading External Innovation” – The strategic goals 2022 2018 2012 2009 Sustainable profitability with positive operating cash flows including milestone Business segmentation and royalty potential Investments to build a world-class Res
Slide 6: "One stop partner" for external innovation
“One stop partner” for external innovation Evotec’s integrated offering and core competences along the value chain Pre- Hit- Lead Target ID/ clinical identi- optimi- IND Phase I Phase II Phase III Approval Market validation Tox fication sation testing Evotec offers end-to-end platform solutions incl
Slide 7: Unique disease expertise coming together
Unique disease expertise coming together Global footprint – Evotec’s centres of excellence Hamburg (HQ), Abingdon, Toulouse + Lyon Verona (Italy), Princeton, Göttingen, Alderley Park (France) Basel (CH) Watertown, Munich (Germany) (UK) Branford (USA) ~520 employees ~650 employees ~370 + ~100 employe
Slide 8: ONE stop-shop for external innovation
ONE stop-shop for external innovation The business model – EVT Execute & EVT Innovate PAGE 7
Slide 9: Agenda
Agenda Overview EVT Execute EVT Innovate Financials & Outlook PAGE 8
Slide 10: No 1 in quality and R&D efficiency
No 1 in quality and R&D efficiency EVT Execute – Comprehensive integrated service offering PAGE 9
Slide 11: Balanced customer mix
Balanced customer mix EVT Execute – Selected KPIs H1 2018 in % Revenues by customer segment ytd1) Customer type ytd1) Revenues by region ytd1) 100% 100% 100% Mid-sized 12% RoW 2% Remaining Pharma 15% 4% 25% Top 11-30 40% Foun- 14% 9% 39% USA customers dations 44% 18% Biotech 24% 37% 13% Top 10 long-
Slide 12: Agenda
Agenda Overview EVT Execute EVT Innovate Financials & Outlook PAGE 11
Slide 13: Building co-owned pipeline with superior platforms and first-in-class targets
Building co-owned pipeline with superior platforms and first-in-class targets EVT Innovate – Initiatives PAGE 12
Slide 14: Fully invested co-owned pipeline
Fully invested co-owned pipeline with approx. 100 programmes Partnership portfolio Molecule Therapeutic Area / Indication Partner Discovery Pre-clinical Phase I Phase II EVT201 CNS – Insomnia BAY-1817080 Chronic cough Phase II start EVT401 Immunology & Inflammation ND1) Oncology Clinical ND1) Oncolo
Slide 15: Partnership in targeted protein degradation
Partnership in targeted protein degradation Celgene & Evotec – Protein Degradation Attractive and promising approach addressing “undruggable” targets via targeted protein degradation Leveraging Evotec’s proprietary Panomics platform, including data analytics platform ‘PanHunter’ Activities mai
Slide 16: Long-term strategic solid tumour partnership
Long-term strategic solid tumour partnership Celgene & Evotec – Expansion of relationship into oncology Strategic oncology partnership with Celgene Long-term strategic drug discovery and development partnership to identify new therapeutics in oncology Initial focus on solid tumours, leveraging a
Slide 17: Ground-breaking initiative to combat ID
Ground-breaking initiative to combat ID Sanofi & Evotec – Definitive agreement closed effective 01 July 2018 Pipeline & Innovation Financials Addition of > 100 scientists with Initial, one-time upfront cash significant expertise and payment of € 60 m and capabilities in infectious significant fu
Slide 18: Global leadership in iPSC
Global leadership in iPSC Strong focus on iPSC1) platform “IPS cells can become a power- Disease-specific drugs ful tool to develop new drugs to cure Screening intractable di- Patient seases because they can be made from patients’ somatic cells.” Disease Patient- in a dish specific Shinya iPSCs Yama
Slide 19: Building BRIDGEs over the "Valley of death"
Building BRIDGEs over the “Valley of death“ The funding gap Basic Applied Technology Development Product Commercialisation Market Entry Research Research and Demonstration and Market Development and Market Volume Public Market Funding Level Pension Plan Project Governments Finance Funding Gap Banks/
Slide 20: Agenda
Agenda Overview EVT Execute EVT Innovate Financials & Outlook PAGE 19
Slide 21: Strong performance continues
Strong performance continues Financial history 2014-2018 (e) – Selected performance indicators Total Group revenues (in € m) R&D expenses (in € m) 257.6 18.3 18.1 17.6 164.5 12.7 127.7 89.5 2014 2015 2016 2017 2018(e) 2014 2015 2016 2017 2018(e) Adjusted Group EBITDA (in € m) Gross margin1) (in %) 5
Slide 22: Increased momentum in both segments
Increased momentum in both segments Segment information H1 2018 – Evotec AG and subsidiaries in € m1) Inter- EVT EVT segment Evotec New business mix with different Execute Innovate elimination Group margin since Aptuit acquisition Revenues 163.3 32.0 (21.5) 173.8 Growth in EVT Execute driven by
Slide 23: Strong team and shareholders for innovation
Strong team and shareholders for innovation Management & shareholder structure ̴ 9% Roland >5% >3% AGI3) Oetker/ROI DAMI2) Management Board Supervisory Board >3% Goldman Sachs Werner Lanthaler (CEO) Wolfgang Plischke Long-time experience in Ex-Bayer >3% BlackRock, Inc. Pharma & biotech Bernd H
Slide 24: Guidance confirmed, R&D guidance updated
“Guidance confirmed, R&D guidance updated following ID initiative1) Guidance 2018 Double- 1 digit top- More than 30% Group revenue growth line growth Profitable 2 Adjusted Group EBITDA2) expected to improve by approx. 30% and growing Focused 3 Group R&D expenses of € 35-45 m1) (previously: € 2
Slide 25: Your contact: Enno Spillner
Your contact: Enno Spillner Chief Financial Officer +49.(0).40.560 81-238 +49.(0).40.560 81-333 Fax enno.spillner@evotec.com
Evotec — Bank of America Merrill Lynch Global Healthcare Conference 2018 on 6ix